King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

King Pharmaceuticals vs. Alpharma

In August 2008, King Pharmaceuticals tried to woo Alpharma with $1.38 billion cash offer. King wasn't prepared to take no for an answer, and it was ready to get hostile if necessary to push the acquisition through.

But Alpharma wasn't as enthusiastic and rejected the offer. Alpharma claimed it had other companies interested in a buyout, but King pushed forward with the hostile bid. King also threatened a proxy battle if Alpharma continued to reject its offers.

Despite Alpharma's repeated objections, a $1.6 billion offer eventually piqued its interest

King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma
Read more on

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.